Liver disorders are one of the major causes of morbidity and mortality all over the world. Drug-induced hepatic toxicity is one of the main cause of liver diseases, and accounts for increasing number of hospital admissions.\[[@ref1]\] Natural plant products have been globally used for the prevention and treatment of hepatic disorders and scientifically proven for their medicinal efficacy.\[[@ref2]\] DRDC/AY/8060 is a new polyherbal formulation developed for prevention and treatment of the liver disorder. It contains the Aqueous extracts of Amlaki bhumi (*Phyllanthus niruri*) Aerial part, Guduchi (*Tinospora cordifolia*), Neem (*Azadirachta indica*) bark, Kalmegh (*Andrographis paniculata*) whole plant, Harataki (*Terminalia chebula*) chhal, Amla (*Emblica officinalis*) dry, bhera (*Terminalia belerica*) chhal, and Kutki (*Picrorhiza kurroa*) roots. The present study was undertaken to evaluate the hepatoprotective potential of DRDC/AY/8060 against paracetamol and D-galactosamine induced hepatic toxicity in Wistar rats.

Materials and Methods {#sec1-1}
=====================

Animals {#sec2-1}
-------

Male Wistar albino rats weighing 200--250 g were used for the study. The animals were maintained under standard laboratory conditions and were allowed free access to food pellets (Ashirwad Industries, Chandigarh) and water *ad libitum*. The study protocol was approved by Institutional Animal Ethics Committee of Jamia Hamdard.

Paracetamol induced hepatic toxicity {#sec2-2}
------------------------------------

Animals were randomly divided into six groups (*n* = 6/group) and treated as follows:

Group 1 (control): Normal saline, 1 ml/kg for 10 daysGroup 2 (toxicant): Paracetamol 750 mg/kg p.o. every 72 h for 10 daysGroup 3 (standard 1): Liv52 p.o. for 10 days along with paracetamol 750 mg/kg p.o. every 72 h for 10 daysGroup 4 (standard 2): Livfit p.o. for 10 days along with paracetamol 750 mg/kg p.o. every 72 h for 10 daysGroup 5 (formulation dose 1): Formulation 8060, 120 mg/kg p.o. for 10 days, along with paracetamol 750 mg/kg p.o. every 72 h for 10 daysGroup 6 (formulation dose 2): Formulation 8060, 240 mg/kg p.o. for 10 days along with paracetamol 750 mg/kg p.o. every 72 h for 10 days.

D-galactosamine induced hepatic toxicity {#sec2-3}
----------------------------------------

Animals were randomly divided into six groups (*n* = 6/group) and treated as follows:

Group I (control): Normal saline, 1 ml/kg for 14 daysGroup II (toxicant): D-galactosamine 400 mg/kg i.p. single doseGroup III (standard 1): Liv52 p.o. for 14 days, D-galactosamine 400 mg/kg i.p. the single dose was co-administered on 14^th^ dayGroup IV (standard 2): Livfit p.o. for 14 days, D-galactosamine 400 mg/kg i.p. the single dose was co-administered on 14^th^ dayGroup V (formulation dose 1): Formulation 8060, 120 mg/kg p.o. for 14 days, D-galactosamine 400 mg/kg i.p. the single dose was co-administered on 14^th^ dayGroup VI (formulation dose 2): Formulation 8060, 240 mg/kg p.o. for 14 days, D-galactosamine 400 mg/kg i.p. the single dose was co-administered on 14^th^ day.

Biochemical and histopathological evaluation {#sec2-4}
--------------------------------------------

Blood was collected from the tail vein of animals 48 h after the completion of the treatment, allowed to coagulate and centrifuged to collect serum at 27°C. Following these animals were sacrificed, and liver tissue was removed for estimation of lipid peroxidation and glutathione (GSH) levels and histopathological studies. Biochemical estimation of serum glutamate oxaloacetate transferase (SGOT), serum glutamate pyruvate transferase (SGPT), albumin, bilirubin, and alkaline phosphatase (ALP) levels was carried out using commercially available kits.

Results and Discussion {#sec1-2}
======================

Paracetamol induced hepatic toxicity {#sec2-5}
------------------------------------

The effect of various treatments on hepatic biochemical parameters is shown in [Table 1](#T1){ref-type="table"}. Paracetamol caused hepatic toxicity in the toxicant group as evident from significantly (*P* \< 0.001, vs. toxicant) elevated levels of SGOT, SGPT, serum bilirubin, and ALP, as well as increased lipid peroxidation and significantly reduced (*P* \< 0.001, vs. toxicant) level of serum albumin and tissue GSH compared to toxicant. However, both the standard drugs (Liv52 and Livfit) significantly (*P* \< 0.001) improved these parameters showing positive shifts of values toward control groups compared to toxicants \[[Table 1](#T1){ref-type="table"}\]. Treatment with formulation 8060 at 120 mg/kg and 240 mg/kg showed significant reduction (*P* \< 0.001) of serum SGOT and SGPT levels in comparison to the toxicant group. Improvement in serum SGOT level was comparatively better (*P* \< 0.001) at 240 mg/kg than 120 mg/kg dose. Similarly, treatment with formulation 8060 at doses of 120 and 240 mg/kg also reduced increased serum ALP and bilirubin levels significantly (*P* \< 0.001 vs. toxicant). Treatment with paracetamol significantly reduced serum albumin and tissue GSH levels compared to control group (*P* \< 0.001 vs. control), whereas, animals treated with formulation 8060 showed significant improvement (*P* \< 0.001 vs. toxicant) in serum albumin and tissue GSH level. Lipid peroxidation was evident from significantly increased (*P* \< 0.001) malondialdehyde (MDA) level in hepatic tissue of the paracetamol (toxicant) treated groups were significantly higher (*P* \< 0.001 vs. control) compared to normal animals. However, treatment with test formulation (8060) significantly reduced (*P* \< 0.001 vs. toxicant) elevated MDA level. These results histopathological evaluation \[[Figure 1](#F1){ref-type="fig"}\] were in accord with biochemical parameters.

###### 

Results of estimation of hepatic biomarkers in different treatment groups against paracetamol-induced hepatic toxicity
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![Histology of hepatic tissue of different treatment groups against paracetamol-induced hepatic toxicity. (a) Control group with normal histological features, (b) toxicant group necrotic areas and vacuole formation, (c) and (d) showing almost normal histology after treatment with DRDC/AY/8060 at 120 mg/kg and 240 mg/kg, respectively. (e) Normal architecture of hepatic tissue in animals treated with standard silymarin](JPBS-7-246-g002){#F1}

D-galactosamine induced hepatic toxicity {#sec2-6}
----------------------------------------

The results of biochemical estimations of various treatment groups treated against D-galactosamine induced hepatic toxicity are shown in [Table 2](#T2){ref-type="table"}. Estimation of biochemical parameters showed that D-galactosamine caused hepatic in the toxicant group as evidenced from significantly (*P* \< 0.001, vs. toxicant) elevated SGOT, SGPT, serum bilirubin, and ALP levels, as well as significantly reduced (*P* \< 0.001, vs. toxicant) level of serum albumin. D-galactosamine also caused increased lipid peroxidation and reduced GSH levels in treated animals. Treatment with standard 1 and standard 2 (i.e., Liv52 and Livfit, respectively) significantly (*P* \< 0.001) reduced the elevated levels of SGOT, SGPT, serum bilirubin, ALP, and tissue MDA. Formulation 8060 significantly reduced (*P* \< 0.001) SGOT and SGPT levels in comparison to toxicant group at both 120 mg/kg and 240 mg/kg. Improvement in both SGOT and SGPT levels were comparatively better (*P* \< 0.001) at the dose of 240 mg/kg vs. 120 mg/kg. Similarly, treatment with formulation 8060 at doses of 120 and 240 mg/kg also reduced increased serum ALP and bilirubin levels significantly (*P* \< 0.001 vs. toxicant). Comparatively better reduction in the bilirubin levels was observed at the higher dose (240 mg/kg) of formulation 8060. Further treatment with formulation 8060 significantly improved (*P* \< 0.001 vs. toxicant) the levels of albumin and GSH in serum and tissue, respectively. Elevated Lipid peroxidation measured as liver tissue MDA level showed significant reduction after treatment with formulation (8060) (*P* \< 0.001 vs. toxicant) at 120 and 240 mg/kg doses. Histopathological observations were found in concurrence with the results of biochemical estimations \[[Figure 2](#F2){ref-type="fig"}\].

###### 

Results of estimation of hepatic biomarkers in different treatment groups against D-galactosamine induced hepatic toxicity

![](JPBS-7-246-g003)

![Histology of hepatic tissue of different treatment groups against D-galactosamine induced hepatic toxicity. (a) Control group with normal histological features, (b) toxicant group necrotic areas and vacuole formation, (c) and (d) showing almost normal histology after treatment with DRDC/AY/8060 at 120 mg/kg and 240 mg/kg, respectively. (e) The normal architecture of hepatic tissue in animals treated with standard silymarin](JPBS-7-246-g004){#F2}

Formulation 8060 contains different established herbal drugs. Bishayi *et al*. have suggested that treatment by *T. cordifolia* extract may be the critical remedy for improving CCl~4~ induced liver dysfunction, as well as immune functions.\[[@ref3]\] *P. niruri* and *A. indica* have also been shown to be protective against drug-induced hepatic oxidative stress.\[[@ref4][@ref5]\] Andrographolide, the major active antihepatotoxic principle present in *A. paniculata* are also reported to reduce CCl~4~-induced hepatic enzyme levels.\[[@ref6]\] Similarly, *T. chebula* is also reported to have hepatoprotective activity, which is attributed to its prominent anti-oxidative and membrane stabilizing activities.\[[@ref7]\] *E. officinalis* extract has been found to reduce elevated levels of hepatic biomarkers, indicating that the extract could inhibit the induction of fibrosis in rats.\[[@ref8]\] Protective effects of *T. belerica* have been shown on microsomal lipid peroxidation and triglycerides in the liver suggest a restorative effect in the process of liver damage.\[[@ref9]\] Like all other components, *P. kurroa* has shown hepatoprotective activity. It also reduced the lipid content liver more significantly the standard dose of the known hepatoprotective silymarin.\[[@ref10]\] All these reports are suggestive of strong hepatoprotective activity of formulation 8060 against the two toxicants.

Conclusion {#sec1-3}
==========

The polyherbal DRDC/AY/8060 possesses good hepatoprotective activity.

Financial support and sponsorship {#sec2-7}
---------------------------------

Nil.

Conflicts of interest {#sec2-8}
---------------------

There are no conflicts of interest.
